CSF1 and COVID-19: Specifically, the development of both ARDS and AKI in COVID-19 patients is associated with IL-1RA, fractalkine, M-CSF, G-CSF, IL-6, and TNF-α, and supports the potential deleterious effect of the “cytokine storm” on disease progression15, 21.